27 January 2020 - Jubilant Radiopharma announced today that the company received approval from Health Canada for Drax Exametazine (Kit for the Preparation of Tc99m exametazime for leukocyte labelling). 

Leukocyte labelling scintigraphy is a nuclear medicine imaging procedure that helps physicians localise an intra-abdominal infection and inflammatory bowel disease.

Drax Exametazime, which is currently approved in the United States, is a radiopharmaceutical used in nuclear medicine (a medical imaging specialty) to help doctors locate infection in a patient when a source of the infection cannot be accurately identified. Identifying the source of the infection is imperative for the proper diagnosis and characterisation of disease and a crucial first step in defining a treatment plan for the patient.

Read Jubilant Pharma press release